Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

被引：0
作者：
Rong Shi
Tong Lu
Grace Ku
Hao Ding
Tomohisa Saito
Leonid Gibiansky
Priya Agarwal
Xiaobin Li
Jin Yan Jin
Sandhya Girish
Dale Miles
Chunze Li
Dan Lu
机构：
[1] Genentech Inc.,
[2] Chugai Pharmaceutical Co.,undefined
[3] Ltd.,undefined
[4] QuantPharm LLC,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
Ethnic sensitivity assessment; NHL; Non-hodgkin lymphoma; PK; Polatuzumab vedotin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：347 / 359
页数：12
相关论文
共 50 条
  • [21] Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma
    Dang, Nam H.
    Fayad, Luis
    McLaughlin, Peter
    Romaguara, Jorge E.
    Hagemeister, Fredrick
    Goy, Andre
    Neelapu, Sattva
    Samaniego, Felipe
    Walker, Pamela L.
    Wang, Michael
    Rodriguez, Maria A.
    Tong, Ann T.
    Pro, Barbara
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (04) : 502 - 505
  • [22] Polatuzumab Vedotin in Combination with Bendamustine Plus Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Our Experience
    Darcin, Tahir
    Yigenoglu, Tugce Nur
    Sahin, Derya
    Bakirtas, Mehmet
    Basci, Semih
    Merdin, Alparslan
    Yildiz, Jale
    Ulu, Bahar Uncu
    Tetik, Aysegul
    Iskender, Dicle
    Cakar, Merih Kizil
    Dal, Mehmet Sinan
    Altuntas, Fevzi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S249 - S250
  • [23] Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey
    Dal, Mehmet Sinan
    Ulu, Bahar Uncu
    Uzay, Ant
    Akay, Olga Meltem
    Besisik, Sevgi
    Yenerel, Mustafa Nuri
    Celik, Serhat
    Kaynar, Leylagul
    Yucel, Orhan Kemal
    Deveci, Burak
    Sonmez, Mehmet
    Mehtap, Ozgur
    Bekoz, Huseyin Saffet
    Sunu, Cenk
    Salim, Ozan
    Ulas, Turgay
    Karti, Sami
    Altuntas, Fevzi
    Ferhanoglu, Burhan
    Tuglular, Tulin Firat
    ANNALS OF HEMATOLOGY, 2023, 102 (01) : 133 - 140
  • [24] A phase 2 study of polatuzumab vedotin plus bendamustine plus rituximab in relapsed/refractory diffuse large B-cell lymphoma
    Terui, Yasuhito
    Rai, Shinya
    Izutsu, Koji
    Yamaguchi, Motoko
    Takizawa, Jun
    Kuroda, Junya
    Ishikawa, Takayuki
    Kato, Koji
    Suehiro, Youko
    Fukuhara, Noriko
    Ohmine, Ken
    Goto, Hideki
    Yamamoto, Kazuhito
    Kanemura, Nobuhiro
    Ueda, Yasunori
    Ishizawa, Kenichi
    Kumagai, Kyoya
    Kawasaki, Atsuko
    Saito, Tomohisa
    Hashizume, Misato
    Shibayama, Hirohiko
    CANCER SCIENCE, 2021, 112 (07) : 2845 - 2854
  • [25] Promising Tolerability and Efficacy Results from Dose-Escalation in an Ongoing Phase Ib/II Study of Mosunetuzumab with Polatuzumab Vedotin (Pola) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
    Budde, Elizabeth
    Ghosh, Nilanjan
    Chavez, Julio
    Lossos, Izidore S.
    Mehta, Amitkumar
    Dorritie, Kathleen
    Kamdar, Manali
    Negricea, Raluca
    Song Pham
    Hristopoulos, Maria
    Huw, Ling-Yuh
    O'Hear, Carol
    Oki, Yasuhiro
    To, Iris
    Diefenbach, Catherine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S393 - S394
  • [26] Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience
    Segman, Yafit
    Ribakovsky, Elena
    Avigdor, Abraham
    Goldhecht, Yair
    Vainstein, Vladimir
    Goldschmidt, Neta
    Harlev, Shimrit
    Horwitz, Netanel
    Gutwein, Odit
    Gurion, Ronit
    Itchaki, Gilad
    Abadi, Uri
    Nemets, Anatoly
    Sofer, Orit
    Zektser, Miri
    Tadmor, Tamar
    Dally, Nagib
    Filanovsky, Kalman
    Leiba, Merav
    Sarid, Nadav
    Benyamini, Noam
    Herishanu, Yair
    Ram, Ron
    Perry, Chava
    Avivi, Irit
    LEUKEMIA & LYMPHOMA, 2021, 62 (01) : 118 - 124
  • [27] Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
    Argnani, Lisa
    Broccoli, Alessandro
    Pellegrini, Cinzia
    Fabbri, Alberto
    Puccini, Benedetta
    Bruna, Riccardo
    Tisi, Maria Chiara
    Masia, Francesco
    Flenghi, Leonardo
    Nizzoli, Maria Elena
    Musso, Maurizio
    Salerno, Marilena
    Scalzulli, Potito Rosario
    Dessi', Daniela
    Ferrarini, Isacco
    Pennese, Elsa
    Lucchini, Elisa
    Rossi, Francesca Gaia
    Minoia, Carla
    Gherlinzoni, Filippo
    Musto, Pellegrino
    Patti, Caterina
    Stefoni, Vittorio
    Zinzani, Pier Luigi
    HEMASPHERE, 2022, 6 (12): : E798
  • [28] Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab
    Saburi, Masuho
    Sakata, Masanori
    Kodama, Yousuke
    Uraisami, Keiichi
    Takata, Hiroyuki
    Miyazaki, Yasuhiko
    Wada, Junpei
    Urabe, Shogo
    Ohtsuka, Eiichi
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2023, 63 (03) : 201 - 204
  • [29] Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis
    Wang, Jianhong
    Duan, Xiaohui
    Yang, Lijie
    Liu, Xiangxiang
    Hao, Caixia
    Dong, Hongjuan
    Gu, Hongtao
    Tang, Hailong
    Dong, Baoxia
    Zhang, Tao
    Gao, Guangxun
    Liang, Rong
    CELL TRANSPLANTATION, 2020, 29
  • [30] Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan
    Izutsu, Koji
    Ando, Kiyoshi
    Nishikori, Momoko
    Shibayama, Hirohiko
    Teshima, Takanori
    Kuroda, Junya
    Kato, Koji
    Imaizumi, Yoshitaka
    Nosaka, Kisato
    Sakai, Rika
    Hojo, Seiichiro
    Nakanishi, Tadashi
    Rai, Shinya
    CANCER SCIENCE, 2021, 112 (09) : 3627 - 3635
12345